Skip to content
Precision for Medicine
Press Release

Precision Continues Asia-Pacific Expansion with Opening of Japan Office

patient-recruitement-2

Patient Recruitment Strategies

Finding the right patients for your trial can be challenging, especially when affected populations are small, such as for rare disease trials. Contact Us
Precision’s holistic patient recruitment approach leverages our global reach, extensive network of disease researchers, and patient advocacy groups to assemble a strategy to match the patient to your clinical trial based on your study’s criteria. For targeted therapeutics, we use biomarker-driven screening to find the patients expected to respond to your therapeutic, moving quickly and with confidence in data quality thanks to our in-house specialty lab services.

Smart patient recruitment strategies

Our network spans the globe, just like your patients do

patient_rec_img

Building relationships with communities and specialists

Patient advocacy group relationships and social media outreach help reach into affected communities.

Meanwhile, our established relationships with key opinion leaders and clinical research sites around the globe secure access to a wide range of patient populations.

Case Study: Enrolling a global natural history study: How to find 200 rare patients

A sponsor selected Precision to manage a global natural history study in a rare, X-linked kidney disorder. The study had been recommended by the FDA because there was extremely limited published data on this rare disease—the goal was to characterize renal function and decline in patients with the disease prior to initiating a phase 2/3 clinical study. The study, to be conducted in the United States, Canada, Australia and in Europe, would follow 200+ patients for approximately 2 years.

Enrollment was by far the greatest study challenge, combining a low disease prevalence and a primary target population—young males—with life commitments such as school and work that left little time for participation in a trial that offered no therapeutic benefit for participants and would require traveling to a clinic every 3 to 6 months.

Read the latest insights on Precision’s blog

Discover expert analysis and broaden your understanding through Precision’s Insights on current research, case studies, and trends. 

Read: What the EMA–FDA AI Principles Really Mean for Clinical Development & Regulatory Affairs What the EMA–FDA AI Principles Really Mean for Clinical Development & Regulatory Affairs

Clinical Trials - Regulatory

What the EMA–FDA AI Principles Really Mean for Clinical Development & Regulatory Affairs

|
    has third author: false, (SizeLimitingPyMap: {main={hs_id=195804116748, hs_child_table_id=0, hs_updated_at=1764696930757, hs_published_at=1772549698856, description=John is an experienced regulatory affairs consultant with more than 15 years of professional experience in drug development. He brings a proven track record in providing regulatory strategy, regulatory document development and review, and liaising with regulatory authorities., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/John%20McIntyre.png',altText='John McIntyre',fileId=201584594055}, lastname=McIntyre, PhD, hs_initial_published_at=1757516163742, hs_created_by_user_id=26433386, hs_created_at=1757515873736, hs_is_edited=false, hs_deleted_at=0, name=John, job=Senior Director, Regulatory Strategy, slug=john-mcintyre, hs_updated_by_user_id=26433386}, second={hs_id=195821592097, hs_child_table_id=0, hs_updated_at=1757598947835, hs_published_at=1772549698856, description=An expert in hematology and oncology and a veteran of the FDA with almost nine years of experience, culminating as a Deputy Director for the Division of Hematologic Malignancies 2. Possesses a profound understanding of regulatory strategy, particularly in the development of CAR-T cell therapies, bispecifics and T-cell engagers. Spearheaded initiatives to develop novel endpoints in blood cancer such as minimal residual disease (MRD) in lymphoma and chronic lymphocytic leukemia (CLL.), avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Nicholas%20Richardson.png',altText='Nicholas Richardson',fileId=195817841672}, linkedin=https://www.linkedin.com/in/nicholas-richardson-do-mph-049784113/, team=[{id=163080551773, name='Clinical Solutions Leadership'}], lastname=Richardson, DO, MPH, hs_initial_published_at=1757528527317, hs_created_by_user_id=51739740, hs_created_at=1757528274871, hs_is_edited=false, hs_deleted_at=0, name=Nicholas, job=Vice President, Clinical Development, slug=nicholas-richardson-clinical-solutions, hs_updated_by_user_id=26433386}, third={hs_id=178046423372, hs_child_table_id=0, hs_updated_at=1754641388766, hs_published_at=1772549698856, description=Rosamund (Roz) Round is a seasoned expert in patient engagement and innovation bringing over 20 years of experience. She is focused on listening to and learning from patients and care partners to understand how to better improve trial access and experience. Roz successfully built and led decentralized clinical trials service through the pandemic and is now addressing the implementation of AI across various aspects of clinical research. She has a strong focus on diversity, equity, and inclusion (DEI) to drive health equity in clinical research. Roz holds an MSc in Health Psychology, studied Psychology and Immunology at Harvard University, and is a recognized thought leader with an extensive portfolio of publications, conference presentations, webinars, and vlogs., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Round-Rosamund.png',altText='Round-Rosamund',fileId=194123714174}, lastname=Round, hs_initial_published_at=1725972637852, hs_created_by_user_id=51739740, hs_created_at=1725972446462, hs_is_edited=false, hs_deleted_at=0, name=Rosamund, job=Vice President, PAtient Engagement & Innovation, slug=rosamund-round, hs_updated_by_user_id=26433386}})
  • John M. avatar Nicholas R. avatar Rosamund R. avatar
  • John M.

    Nicholas R.

    Rosamund R.

Discover
Read: Case Study: Scaling a First Line NSCLC Trial in a Hesitant Market Case Study: Scaling a First Line NSCLC Trial in a Hesitant Market

Oncology

Case Study: Scaling a First Line NSCLC Trial in a Hesitant Market

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=208638641305, hs_child_table_id=0, hs_updated_at=1772549693775, hs_published_at=1772549698856, description=Lisa is a Director, Project Management who has been with Precision since Jan 2019. Lisa has over 18 years of clinical research experience, with a proven track record in leading cross-functional teams across programs of studies. Lisa is a collaborative communicator capable of cultivating key relationships focused on customer satisfaction. In 2018, Lisa was granted the CEO Excellence Award for exceptional project management., avatar=Image{width=378,height=339,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Lisa%20Lopez_Headshot.jpg',altText='Lisa Lopez_Headshot',fileId=208044988231}, lastname=Lopez, hs_initial_published_at=1772549698856, hs_created_by_user_id=26433386, hs_created_at=1772549635830, hs_is_edited=false, hs_deleted_at=0, name=Lisa, job=Director, Project Management, slug=lisa-lopez, hs_updated_by_user_id=26433386}, second={hs_id=208600974006, hs_child_table_id=0, hs_updated_at=1772549671531, hs_published_at=1772549698856, description=Adrien (Ash) Mtibaa, MD is a clinical research leader with 10+ years of experience in global clinical trials and deep expertise in Site Start‑Up (SSU). Currently Manager, Site Start‑Up at Precision for Medicine, he leads and mentors global SSU teams with a strong focus on process improvement, SSU strategy, leadership influence, and line management. A trained Medical Doctor, Adrien brings a pragmatic, results‑driven approach to driving activation readiness, operational excellence, and cross‑functional alignment across multi‑regional studies., avatar=Image{width=800,height=800,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Adrien%20Mtibaa%2c%20MD.jpg',altText='Adrien Mtibaa, MD',fileId=208642032927}, lastname=Mtibaa, MD, hs_initial_published_at=1772549611983, hs_created_by_user_id=26433386, hs_created_at=1772488816847, hs_is_edited=false, hs_deleted_at=0, name=Adrien, job=Manager, Site Start Up, slug=adrien-mtibaa, hs_updated_by_user_id=26433386}, third={}})
  • Lisa L. avatar

    Lisa L.

  • Adrien M. avatar

    Adrien M.

Discover
Read: Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research

Translational Research

Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=199448088864, hs_child_table_id=0, hs_updated_at=1762810484868, hs_published_at=1772549698856, avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Kaylee%20Mueller.png',altText='Kaylee Mueller',fileId=199456336149}, lastname=Mueller, hs_initial_published_at=1762810487482, hs_created_by_user_id=26433386, hs_created_at=1762810467146, hs_is_edited=false, hs_deleted_at=0, name=Kaylee, slug=kaylee-mueller, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Kaylee Mueller avatar

    Kaylee Mueller

Discover